Research & Regulatory News

A Warning Comes Off Three GLP-1 Labels

UKPWritten and published by UK Peptides4 min readUpdated 3 cited sources

The short answer

The FDA has requested that manufacturers remove all language about suicidal ideation and behaviour from the labelling of Saxenda, Wegovy and Zepbound. It follows a meta-analysis of 91 placebo-controlled clinical trials covering 107,910 participants, which found no increased risk of those outcomes.

Key facts

Date
13 January 2026
Action
Request to remove warning language from labelling
Products named
Saxenda (liraglutide), Wegovy (semaglutide), Zepbound (tirzepatide)
Trials in the analysis
91, placebo-controlled
Total participants
107,910
GLP-1-treated
60,338
Placebo
47,572
Outcomes assessed
Suicidal behaviour and ideation, anxiety, depression, irritability, psychosis
Investigation opened
July 2023

What was announced

The FDA issued a Drug Safety Communication on 13 January 2026 requesting that application holders remove information regarding the risk of suicidal ideation and behaviour from the labelling of GLP-1 receptor agonist medications. The named products are Saxenda (liraglutide), Wegovy (semaglutide) and Zepbound (tirzepatide). The basis given is a meta-analysis of 91 placebo-controlled clinical trials drawn from across GLP-1 receptor agonist development programmes, comprising 107,910 participants of whom 60,338 received a GLP-1 receptor agonist and 47,572 received placebo. The analysis found no increased risk of suicidal ideation or behaviour, nor of related psychiatric adverse events including anxiety, depression, irritability and psychosis.

How the question arose

The FDA opened a formal investigation in July 2023 following postmarketing reports of suicidal ideation and behaviour in patients using these medications. Postmarketing reports are the earliest and least reliable form of safety information (voluntary, unverified, without a denominator of exposed people), and their function is to prompt investigation rather than to establish anything. That is what happened here. A preliminary Drug Safety Communication in January 2024 reported no clear evidence of causation while noting that the small number of cases in individual trials left the risk estimate uncertain.

Research material referenced

Retatrutide 10mg, third-party HPLC tested

Buy Retatrutide · £59.99

What Europe did, and when

The European Medicines Agency's Pharmacovigilance Risk Assessment Committee reached its conclusion on 12 April 2024, considerably earlier. Having reviewed non-clinical studies, clinical trials, post-marketing surveillance data and additional studies including one based on electronic health records that the agency conducted itself, the PRAC concluded that the available evidence does not support a causal association between the GLP-1 receptor agonists dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide and suicidal and self-injurious thoughts and actions. Its stated consequence was that no update to the product information was warranted. The UK's MHRA reached a similar conclusion. Strictly, the European decision was not to change the labelling, which is a different act from the FDA's later decision to remove text from it.

Why the trial-level evidence was decisive

The recurring problem in this question is confounding. People prescribed weight-management medicines have, as a group, higher baseline rates of depression and related conditions than the general population, partly because obesity and depression co-occur, partly because the decision to seek treatment is itself associated with distress. Any observational comparison inherits that. A published meta-analysis of observational studies illustrates the consequence: pooling four studies gave a risk ratio of 0.568 with a 95% confidence interval from 0.077 to 4.205 and heterogeneity of 98%, an estimate compatible with almost any conclusion. Randomised allocation across 91 trials removes the confounding by construction and supplies the event numbers that individual trials lacked.

What this does not establish

That the risk is zero. A large randomised analysis constrains how large an effect could have escaped detection; it does not prove absence, and no study design does. It also does not extend beyond the populations enrolled, the durations studied or the products analysed. Commentary accompanying these reviews has continued to recommend monitoring of mental health in people with existing psychiatric conditions, which remains a matter for prescribing clinicians rather than for labelling.

Why this belongs in a peptide reference library

Because it is a complete, dated, publicly documented example of a safety signal being opened, investigated across two regulatory systems and formally closed, which is rare. Most signals persist unresolved. It is also a demonstration of the gulf between what exists for licensed medicines and what exists for research material: three products here have a 107,910-participant randomised safety database and labelling that regulators actively revise. Compounds supplied for laboratory research have none of that, and no article on this site should ever be read as suggesting otherwise.

Frequently asked questions

Has the warning been removed already?

The FDA requested removal from application holders; implementing a labelling change is a process rather than an instant event, and other jurisdictions make their own decisions. The action to date is the request and the review supporting it.

Does this apply to all GLP-1 drugs?

The FDA communication names Saxenda, Wegovy and Zepbound. The EMA's earlier review covered dulaglutide, exenatide, liraglutide, lixisenatide and semaglutide. Neither statement covers every compound in the class, and investigational agents have no labelling to change.

Why did this take two and a half years?

Because assembling participant-level data across 91 trials from multiple development programmes is a substantial undertaking, and because removing a warning requires more evidence than declining to add one. The delay reflects the evidentiary standard rather than inaction.

Does this change anything for someone taking one of these medicines?

It changes what the label says, not what any individual should do. Decisions about a prescription belong with the prescribing clinician. Nothing supplied on this site is a version of or an alternative to any of these medicines.

Continue researching

Related guides and reference material.

Primary sources & clinical trials

Published papers, trial registrations, regulator pages and company announcements. Links open the original.

UKP

Written and published by UK Peptides, the trading name of AURYXRESEARCH LTD (company 17388727, registered in England and Wales).

Questions or a correction? Email hello@ukpeptides.org or call +44 7426 987848.

Corrections log

More Research & Regulatory News articles

Research use only. The information above is provided for scientific and educational reference. Compounds referenced are not approved for human use and are supplied for in vitro research or reference-material purposes only. No efficacy, safety, or therapeutic claims are made.